In injectable manufacturing, Salvia total phenolic acids are processed as a sterile aqueous solution for parenteral administration in cattle, swine, or companion animals. Because the free acid form has limited aqueous solubility at neutral pH, the API is converted to a sodium salt or meglumine salt during charge-in, with pH adjusted to 5.5–6.5 using 0.1 M NaOH or 0.1 M HCl. The compounding vessel is a 316L stainless steel jacketed tank with bottom magnetic stirrer, nitrogen overlay, and 0.22 µm vent filtration. A typical batch is targeted to an assayed total phenolic acids concentration expressed as salvianolic acid B equivalent, not by nominal input weight alone, because batch-to-assay variation of botanical-derived phenolic acids can exceed 3% if source material is not controlled. The vehicle consists of Water for Injection q.s., sodium chloride added to achieve 280–320 mOsm/kg, sodium metabisulfite at 0.05–0.1% w/v, and disodium edetate at 0.01% w/v as an antioxidant and metal-ion chelator. Mixing proceeds at 300 rpm for 20 min until a clear solution is obtained. The solution is prefiltered through a 0.45 µm polyvinylidene fluoride membrane and sterilized by passage through a 0.22 µm sterilizing-grade membrane; terminal steam sterilization at 121°C for 15 min is evaluated only if forced degradation studies demonstrate marker recovery within the pre-specified release limit, otherwise aseptic filtration is specified. Finished vials are filled on a peristaltic-pump filling line into depyrogenated Type I borosilicate glass vials with chlorobutyl rubber closures, with headspace nitrogen flushing before stoppering. The injectable is tested for bacterial endotoxin by USP <85>, sterility by USP <71>, particulate matter by USP <788>, and HPLC assay by USP <621> with a C18 column, 1.0 mL/min flow rate, and UV detection at 280 nm. The solution is incompatible with strong oxidizing agents and with prolonged contact with iron or copper surfaces; stainless steel passivation with citric acid is required after caustic cleaning. The product is stored in amber vials protected from light, and freezing must be avoided because phenolic acid salts may precipitate on thawing.

What Limits Metering Accuracy in High-Humidity Drinking-Water Dosing Systems?

Drinking-water medication presents a process conflict that is driven less by active assay than by particle size distribution and hygroscopicity of the powder blend. The powder is manufactured by blending milled API with anhydrous dextrose or maltodextrin and sodium citrate as a dispersing and buffering agent. The API is pre-sieved through a 0.300 mm stainless steel mesh to break agglomerates, and the total blend is mixed in a low-shear ribbon mixer with 70% occupancy at 12 rpm for 15 min. Sampling is performed at 10 thief points; the relative standard deviation of total phenolic acid content must be ≤ 5% before discharge. Processing rooms are maintained at 18–22°C and ≤ 45% RH because phenolic acid salts are hygroscopic and may form lumps at higher ambient moisture. Powder is packed in foil-lined heat-sealed bags with desiccant sachets; an open bag is consumed within 7 days or discarded if the powder contains visible agglomerates. The end user prepares a stock solution in a proportioner bucket calibrated to 1:100 or 1:200; before connecting to the medicated water line, the operator verifies pump output with a graduated cylinder because backpressure from drinker nipples can reduce actual metering volume by 5–15% depending on line pressure. Water with carbonate hardness above 150 mg/L CaCO₃ may require citric acid pre-treatment; free chlorine above 2 mg/L oxidizes phenolic acids rapidly, so chlorinated water must be neutralized with sodium thiosulfate before mixing. The stock solution is prepared fresh daily and must not be held beyond 6 h at ambient temperature in the absence of a preservative. Content uniformity of the powder in sachets is tested by USP <905> adapted to single-dose powder weight, with acceptance value ≤ 15. The finished product is labelled for use in swine and poultry drinking-water systems with a statement that it must not be combined with acidic vitamin concentrate in the same stock bucket.

When Feed Granulation Steam Exceeds 70°C, Phenolic Acid Recovery Falls Sharply

Feed premix manufacturing begins with the dilution of the active ingredient onto a carrier such as ground corncob, rice hulls, or calcium carbonate in a double-cone tumbler mixer of 1000 L capacity operating at 8 rpm for 20 min. The mixer is discharged through a 0.5 mm sieve to remove carrier fines and metal fragments. Homogeneity is verified by collecting 10 samples with a thief sampler across the batch; the coefficient of variation for salvianolic acid B must be below 5% to ensure that each 25 kg bag meets the label claim. When the premix is incorporated into compound feed, the pelleting step is the critical control point. Steam conditioning at 75–85°C for 30–60 s may reduce marker content depending on moisture, pressure, and dwell time; published data for this specific API under commercial pelleting conditions is limited, so a pilot-scale trial is required at each line speed before full production. If a granulated premix is produced, top-spray fluid bed granulation uses povidone K30 at 3–5% w/w as binder, inlet air at 60–70°C, product temperature 30–35°C, spray rate 80–120 g/min for a 25 kg batch, and final sieving between 2.0 mm and 0.250 mm. Residual moisture is controlled to ≤ 4.0% by Karl Fischer titration per USP <921>. Because fine phenolic acid particles adhere electrostatically to polypropylene and steel contact surfaces, cleaning validation must include rinse and swab sampling for the next batch; a carryover threshold of 0.1% of the next batch size is applied. The finished premix is packed in 25 kg multi-wall paper bags with an inner polyethylene liner, and the label states for use in feed manufacture only. Sampling and analysis of the finished feed may be conducted according to Commission Regulation (EC) No 152/2009 if intended for the EU market. The product is not recommended for use in extruded feed where barrel temperatures exceed 90°C unless a protected granulated form is validated.

Because direct compression of unmilled Salvia total phenolic acids produces unacceptable weight variation and capping, wet granulation is used for tablet production. The API is delumped through a 1.0 mm screen and blended with microcrystalline cellulose PH102, lactose monohydrate 200 M, croscarmellose sodium 2.0–4.0% w/w, and povidone K30 3.0% w/w in a high-shear granulator. Purified water is added at an impeller speed of 200 rpm and chopper speed of 1500 rpm for 6–8 min; prolonged wet massing is avoided because the phenolic acid mass becomes sticky and may adhere to granulator walls. The wet mass is passed through a 2.0 mm screen and dried in a fluid bed dryer with inlet air at 60°C and product temperature 38–42°C until loss on drying is 1.5–2.5%. Dried granules are milled through a 0.8 mm screen, then lubricated with magnesium stearate 0.75% w/w for 3 min at 15 rpm in a V-blender. Tablet compression is performed on a 16-station rotary press with 8 mm round concave punches; target hardness is 60–100 N, friability ≤ 1.0% per USP <1216>, and disintegration ≤ 15 min in 37°C water per USP <701>. Dissolution is tested by USP <711> Apparatus 2 at 50 rpm in pH 6.8 phosphate buffer; content uniformity is tested by USP <905> with acceptance value ≤ 15. The compressed tablets are film-coated with polyvinyl alcohol-based Opadry II to a 3% weight gain in a perforated pan with inlet air 60–65°C, bed temperature 38–42°C, pan speed 4–8 rpm, and spray rate 15–25 g/min. The coated tablets are packed in PVC/PVDC/aluminum blisters with a desiccant sachet for bottles, because the dosage form shows moisture sorption at RH > 60%. Pre-drying of granules is required at RH > 60%, and open bulk storage must be limited to 24 h under uncontrolled humidity.

HPMC Capsule Filling, Two-Stage Dissolution, and Moisture Sorption Boundaries

Capsule dosage forms use the same dry granulation as tablets but with flowability optimized by adding colloidal silicon dioxide 0.5% w/w and sodium stearyl fumarate 1.0% w/w rather than magnesium stearate, which can reduce dissolution rate at higher levels. The lubricated granules are filled into #1 hard capsules on an automatic capsule machine at 60–80% of maximum speed; fill weight variation must not exceed ±5% and content uniformity is tested per USP <905>. Gelatin capsule cross-linking caused by polyphenolic structures should be considered when dissolution failures occur in the acid stage; switching to hydroxypropyl methylcellulose capsules is a validated corrective action because HPMC shells are not subject to the same aldehyde-mediated cross-linking mechanism. Dissolution is tested by USP <711> using 0.1 N HCl for 2 h followed by pH 6.8 phosphate buffer; if an enteric effect is not claimed, the two-stage method is still used to identify potential precipitation of the phenolic acid in gastric pH. Bulk capsules are stored at 25°C/60% RH; if ambient RH exceeds 60%, the granules must be pre-dried before filling, and silica gel canisters in HDPE containers should maintain headspace relative humidity below 20%. Microbiological examination of finished capsules follows USP <61> and USP <62> with the same acceptance criteria as other non-sterile oral dosage forms. Capsules are packed in 30-count HDPE bottles with induction-sealed lids and a desiccant sachet; the label storage condition is 20–25°C and protection from light.

Oral Solution Preservation Relies on pH, Light Exclusion, and Preservative Efficacy Testing

Aqueous oral solutions for swine and calves are compounded at a target total phenolic acid concentration expressed as salvianolic acid B equivalent in purified water with sorbitol solution 20% w/w, sodium benzoate 0.1% w/v, disodium edetate 0.01% w/v, and citric acid to adjust pH to 6.0–6.5. The batch is mixed in a 500 L 316L stainless steel jacketed vessel with a bottom propeller at 200 rpm until visually clear; the solution is filtered through a 10 µm polypropylene filter to remove undissolved carrier residues. The product is filled into 1 L and 5 L amber HDPE containers with tamper-evident caps; light exclusion is mandatory because phenolic acids absorb in the 290–330 nm range and undergo photooxidation, so containers must meet USP <661.1> light transmission requirements. Preservative efficacy is verified per USP <51> with Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Candida albicans, and Aspergillus brasiliensis, using the compendial acceptance criteria for oral products. The product is stored at 15–25°C; freezing causes precipitation of phenolic acid salts and redissolution after thawing is not guaranteed. When the solution is administered through drinking-water dosing systems, the diluted solution may be exposed to organic matter and light; therefore the diluted preparation should be consumed within 24 h, and no stability beyond that period should be assumed for this API. Contact with copper or brass fittings must be avoided; silicone tubing and polypropylene connectors are recommended for dosing lines. In-use stability studies for a particular farm water source should be performed at the point of use because the presence of high iron or manganese levels can accelerate colour development and reduce active content.